Honasa Shopper Restricted, the mother or father firm of Mamaearth, has reported its highest quarterly revenue so far, as income elevated by 27% within the first quarter of the monetary 12 months ending March 2027. 

The beauty and personal care firm posted a consolidated PAT of Rs 90.45 crore for the three months ended 30 June 2026, in contrast with Rs 41.33 crore in the identical interval a 12 months earlier.

Honasa’s income from operations rose to Rs 755.95 crore from Rs 595.25 crore a 12 months earlier. The corporate additionally earned Rs 22.51 crore in different revenue, bringing its whole revenue for the quarter to Rs 778.46 crore, in line with its unaudited consolidated monetary outcomes filed with the inventory exchanges.

On a sequential foundation, income from operations elevated by about 15% from Rs 657.08 crore within the March quarter, whereas revenue rose by about 30% from Rs 69.44 crore.

Working earnings earlier than curiosity, tax, depreciation and amortisation, or EBITDA, have been reported at about Rs 110 crore, in contrast with about Rs 46 crore a 12 months earlier. The corresponding EBITDA margin rose to about 14.6% from 7.7%.

Honasa’s whole bills elevated to Rs 659.27 crore from Rs 563.55 crore a 12 months in the past. Purchases of traded items rose to Rs 240.24 crore from Rs 170.62 crore, whereas worker profit bills elevated to Rs 66.38 crore from Rs 60.38 crore. Different bills, the corporate’s largest reported expense line, rose to Rs 350.32 crore from Rs 317.66 crore.

The corporate mentioned its focus classes grew by greater than 35% in the course of the quarter. Mamaearth recorded progress within the excessive teenagers, whereas its portfolio of youthful manufacturers grew by greater than 40%. Honasa had indicated comparable developments in a buying and selling replace issued in July, when it mentioned offline distribution and its newer manufacturers have been among the many major drivers of progress.

Honasa mentioned Mamaearth’s Rice Dewy Vivid Face Wash had grow to be the model’s main face cleanser, whereas its Rosemary vary turned the second hair-care ingredient after Onion to exceed Rs 100 crore in annual recurring income, or ARR.

The corporate additionally mentioned The Derma Co. had crossed Rs 1,000 crore in annualised web gross sales worth, whereas its face cleanser enterprise exceeded Rs 200 crore in ARR.

Honasa’s offline distribution continued to broaden, with the corporate saying each Basic Commerce and Trendy Commerce grew by greater than 40%. Its merchandise have been obtainable throughout about 300,000 FMCG shops by the tip of the quarter.

The corporate has additionally entered the perfume market with the launch of FIKN, including one other class to its portfolio of magnificence and private care manufacturers.

Varun Alagh, chairman, CEO and co-founder of Honasa Shopper, mentioned the efficiency confirmed that the corporate’s technique was gaining traction.

“Q1 has bolstered that the technique is working,” Alagh mentioned. “Our Focus Classes grew 35%+, and we’re seeing stronger demand throughout Basic Commerce, Trendy Commerce and eCommerce. That is the playbook we got down to construct, and it’s now translating into efficiency,” he mentioned. 

Honasa has additionally been increasing by means of acquisitions. It accomplished the acquisition of a 95% stake in BTM Ventures, which owns males’s private care model Reginald Males, in January 2026. The corporate mentioned in its newest replace that BTM Ventures had since crossed Rs 150 crore in ARR and had greater than doubled in dimension following the acquisition.

Individually, Honasa’s board in June accepted the proposed acquisition of a 58% stake in nutraceuticals firm Fluence Pharma at an enterprise worth of about Rs 135 crore.

The transaction had not been accomplished on the time of Honasa’s Q1 outcomes on 13 August. The corporate mentioned the deal remained topic to closing changes and the completion of situations precedent, and subsequently had no influence on its monetary outcomes for the June quarter.

Honasa plans to accumulate the remaining 42% of Fluence Pharma in two tranches over the 5 to seven years following completion of the preliminary transaction.